Related Experiment Videos
[Indications for irradiated blood components: dose and side effects]
1Abteilung Transfusionsmedizin der Universität Ulm, BRD.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy
|January 1, 1993
Summary
Irradiated blood products prevent transfusion-associated graft versus host disease (ta-GvHD), a rare but fatal complication. This safety measure, implemented for at-risk patients, has shown no adverse effects over four years.
Area of Science:
- Hematology
- Immunology
- Transfusion Medicine
Context:
- Transfusion-associated graft versus host disease (ta-GvHD) is a severe complication in immunocompromised individuals.
- Specific patient groups are at high risk, including bone marrow transplant recipients, infants, and those with severe combined immunodeficiency.
Purpose:
- To outline the critical role of irradiated blood products in preventing ta-GvHD.
- To define the at-risk patient populations requiring this intervention.
- To establish the efficacy and safety of a standardized irradiation protocol.
Summary:
- Irradiated blood products are essential for preventing ta-GvHD in immunocompromised patients.
- High-risk groups include bone marrow transplant patients, infants, individuals with SCID, and those receiving blood from first-degree relatives.
- Irradiation of blood products with at least 30 Gy immediately prior to transfusion is recommended.
Impact:
- The implementation of irradiated blood products has successfully prevented ta-GvHD in at-risk populations.
- A four-year observation period of this protocol revealed no associated complications or side effects.
- This practice significantly enhances transfusion safety for vulnerable patient groups.